IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience

INTRODUCTION:Immune checkpoint inhibitor-mediated colitis (IMC) is commonly managed with steroids and biologics. We evaluated the efficacy of ustekinumab (UST) in treating IMC refractory to steroids plus infliximab and/or vedolizumab.RESULTS:Nineteen patients were treated with UST for IMC refractory to steroids plus infliximab (57.9%) and/or vedolizumab (94.7%). Most of them had grade & GE;3 diarrhea (84.2%), and colitis with ulceration was present in 42.1%. Thirteen patients (68.4%) attained clinical remission with UST, and mean fecal calprotectin levels dropped significantly after treatment (629 & PLUSMN; 101.5 mcg/mg to 92.0 & PLUSMN; 21.7 mcg/mg, P = 0.0004).DISCUSSION:UST is a promising therapy for the treatment of refractory IMC.

Automated summary

This study evaluated the efficacy of ustekinumab in treating immune checkpoint inhibitor-mediated colitis refractory to steroids plus infliximab and/or vedolizumab.